Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,510 | 0,530 | 16.06. | |
0,501 | 0,535 | 16.06. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | |
---|---|---|---|---|
Mi | Veru Inc.: Veru to Participate in the Virtual BTIG Obesity Health Forum | 7 | GlobeNewswire (USA) | |
30.05. | Tootsie Roll among names set to join Russell 3000 Index, Growgeneration, Veru set to leave | 13 | Seeking Alpha | |
30.05. | Beyond Meat, Plby among consumer staple names set to join Russell Microcap Index, Veru, Vitals Farms to leave | 37 | Seeking Alpha | |
28.05. | Muscle-sparing obesity drug safe for Phase 3 trial, Veru says | 30 | BioPharma Dive | |
28.05. | Veru's Enobosarm Shows Muscle In Wegovy Combo Trial | 53 | Benzinga.com | |
28.05. | Veru Inc.: Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide ... | 171 | GlobeNewswire (Europe) | |
08.05. | Veru signals Q3 2025 regulatory clarity for enobosarm Phase 3 trial | 35 | Seeking Alpha | |
VERU Aktie jetzt für 0€ handeln | ||||
08.05. | VERU INC. - 10-Q, Quarterly Report | 1 | SEC Filings | |
08.05. | JTC Team, LLC: JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s Enobosarm Taking GLP-1 Weight Loss to Next Level | 414 | ACCESS Newswire | |
08.05. | Veru Inc.: Veru Participates in a Virtual Investor KOL Connect Segment | 6 | GlobeNewswire (USA) | |
08.05. | VERU INC. - 8-K, Current Report | 3 | SEC Filings | |
08.05. | Veru Inc.: Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress | 549 | GlobeNewswire (Europe) | |
07.05. | A Peek at Veru's Future Earnings | 7 | Benzinga.com | |
07.05. | Veru Q2 2025 Earnings Preview | 4 | Seeking Alpha | |
01.05. | Veru Inc.: Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8 | 8 | GlobeNewswire (USA) | |
16.04. | Veru Inc.: Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit | 12 | GlobeNewswire (USA) | |
14.03. | VERU INC. - 8-K, Current Report | 13 | SEC Filings | |
13.02. | Veru targets Phase 3 enobosarm trials following promising Phase 2b results in obesity treatment | 49 | Seeking Alpha | |
13.02. | VERU INC. - 10-Q, Quarterly Report | 4 | SEC Filings | |
13.02. | Veru Inc.: Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress | 541 | GlobeNewswire (Europe) |